Challenges in maintaining medicine quality while aiming for universal health coverage: a qualitative analysis from Indonesia
Open Access
- 28 May 2021
- journal article
- research article
- Published by BMJ in BMJ Global Health
- Vol. 6 (Suppl 3) , e003663
Abstract
Introduction Indonesia, the world’s fourth most populous nation, is close to achieving universal health coverage (UHC). A widely-publicised falsified vaccine case in 2016, coupled with a significant financial deficit in the national insurance system, has contributed to concern that the rapid scale-up of UHC might undermine medicine quality. We investigated the political and economic factors that drive production and trade of poor-quality medicines in Indonesia. Methods We reviewed academic publications, government regulations, technical agency documents and news reports to develop a semi-structured questionnaire. We interviewed healthcare providers, policy-makers, medicine regulators, pharmaceutical manufacturers, patients and academics (n=31). We included those with in-depth knowledge about the falsified vaccine case or the pharmaceutical business, medicine regulation, prescribing practice and the implementation of UHC. We coded data using NVivo software and analysed by constant comparative method. Results The scale-up of UHC has cut revenues for physicians and pharmaceutical manufacturers. In the vaccine case, free, quality-assured vaccines were available but some physicians, seeking extra revenue, promoted expensive alternatives. Taking advantage of poor governance in private hospitals, they purchased cut-price ‘vaccines’ from freelance salespeople. A single-winner public procurement system which does not explicitly consider quality has slashed the price paid for covered medicines. Trade, industrial and religious policies simultaneously increased production costs, pressuring profit margins for manufacturers and distributors. They reacted by cutting costs (potentially threatening quality) or by market withdrawal (leading to shortages which provide a market for falsifiers). Shortages and physician-promoted irrational demand push patients to buy medicines in unregulated channels, increasing exposure to falsified medicines. Conclusion Market factors, including political pressure to reduce medicine prices and healthcare provider incentives, can drive markets for substandard and falsified medicines. To protect progress towards UHC, policy-makers must consider the potential impact on medicine quality when formulating rules governing health financing, procurement, taxation and industry.Keywords
Funding Information
- Wellcome Trust (209930)
- Erasmus Universiteit Rotterdam (Research Excellence and Innovation)
This publication has 26 references indexed in Scilit:
- Essential medicines for universal health coverageThe Lancet, 2017
- Medicines and universal health coverage: challenges and opportunitiesJournal of Pharmaceutical Policy and Practice, 2015
- Quality use of medicines within universal health coverage: challenges and opportunitiesBMC Health Services Research, 2014
- Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countriesHealth Policy and Planning, 2014
- Strengthening Medical Product Regulation in Low- and Middle-Income CountriesPLOS Medicine, 2012
- Serve the people or close the sale? Profit-driven overuse of injections and infusions in China's market-based healthcare systemThe International Journal of Health Planning and Management, 2011
- ASHP Guidelines on Managing Drug Product Shortages in Hospitals and Health SystemsAmerican Journal of Health-System Pharmacy, 2009
- Pharmaceutical Policy In ChinaHealth Affairs, 2008
- Qualitative research in health care: Analysing qualitative dataBMJ, 2000
- The Discovery of Grounded Theory; Strategies for Qualitative ResearchNursing Research, 1968